This ad will auto close in 10 seconds

Brazil suspends import of Lupin's antibiotic ingredients

Brazilian drug regulator ANVISA has suspended import of active ingredients produced by pharma major Lupin used to make antibiotics, citing "unsatisfactory inputs" and deviation from good manufacturing practices (GMP).

Lupin gets Board's nod to raise funds up to Rs 7,500 crore

Lupin gets Board's nod to raise funds up to Rs 7,500 crore

Drug major Lupin on Tuesday said its Board of Directors have given in-principle approval for raising funds of up to Rs 7,500 crore.

Lupin Q2 net profit up 55% at Rs 630 crore

Drug major Lupin Tuesday posted 55.11 percent rise in its consolidated net profit at Rs 630.04 crore for the second quarter ended September 30, driven by robust sales in the US, Japan and domestic market.

Lupin forms JV with Japan's Yoshindo Inc

Drug major Lupin has entered into a joint venture pact with Toyama-based Yoshindo Inc to form a new entity which will be responsible for development as well as obtaining marketing access for products in the Japanese market.

Lupin expects to launch 20-25 products every year in the US

Drug major Lupin Ltd, the fifth largest generics player in the US, expects to launch 20-25 products in the American market every year in the next couple of years.

Lupin expects sales to grow by around 25% in next 3 yrs

"If the past is prescriptive of the future, then we should continue to grow at the current growth levels -- clock in a minimum growth of 22-25 percent on all counts globally for the next three years," Lupin President (Finance & Planning) and CFO S Ramesh said.

Lupin gets USFDA nod for generic Seasonique tablets

Drug major Lupin Friday said it has received US health regulator's approval for generic version of Teva Branded Pharm's Seasonique Tablets, used to prevent pregnancy, in the American market.

Lupin gets USFDA nod for generic hypertension drug

The Mumbai-based firm said it has already commenced shipping the product.

Lupin receives USFDA nod for Lorazepam Oral Concentrate

Drug firm Lupin Thursday said it has received US health regulator's approval to market its generic Lorazepam Oral Concentrate, used for treating anxiety disorders, in the American market.

Lupin to launch 5-6 products in US market in near future

Lupin expects to launch 5-6 products in the near future out of a total of over 100 products, which are awaiting approvals from the US health regulator, a top company official said Thursday.

Lupin to replicate Japan model for expansion in various mkts

Lupin has established operations in Mexico and Canada and has started filing for products in these markets.

Lupin eyes $300 mn revenues from Japan in next 2 yrs

Drug maker Lupin is eyeing a jump of over 80 percent in its revenues to USD 300 million (about Rs 1,557 crore) from the Japanese market in the next two years on the back of its enhanced presence in the country.

Jhunjhunwala hikes Lupin stake to nearly 3%

Renowned investor Rakesh Jhunjhunala, along with his wife Rekha, has hiked his stake in drugmaker Lupin Ltd to nearly 3 percent by adding 14.04 lakh shares, worth about Rs 65 crore, to his holding in past three months.